A US study of more than a million Medicaid enrollees, newly diagnosed with opioid use disorder (OUD), finds most – nearly seven in 10 – are not receiving access to potentially life-saving drugs within six months. 

Competitive pricing is a consumer’s best defense against overpayment.

The American Society for Nutrition (ASN) and ASN Foundation (ASNF) are proud to announce the launch of new ASN Student Member Scholarships, a transformative initiative providing complimentary ASN memberships to every graduate student enrolled in Academic Nutrition Departments and Programs (ANDP) member institutions beginning January 2026. ANDP, a community within ASN, is comprised of directors of undergraduate and graduate nutrition departments and programs across the United States who work collectively to advance nutrition education, share best practices, influence policy, and strengthen student recruitment. This scholarship program directly supports that mission.  

A combination of outreach methods – including texts, automated messages, and live phone calls – can significantly improve follow-up care for hard-to-reach patients after they have been discharged, according to a new nursing study from UCSF Health.

The Herbert Wertheim School of Public Health and Human Longevity Science at University of California San Diego is expanding its roadway safety education efforts to reach more Californians, with a focus on Native American youth, pedestrian safety and Spanish-speaking communities.

It’s boomtime for corporate psychedelia.

In the past few weeks, biotech startup MindMed secured $259m to fund its development pipeline, and competitors atai Life Sciences and Beckley Psytech merged to form AtaiBeckley.

Despite the hype around the benefits of psychedelics for mental health treatment, political economist Dr Sandy Brian Hager warns the “shroom boom” may be heading for a bust.

His study suggests investors could be spooked once more, because:

- Difficult to patent: Psychedelics cannot easily be patented, which turns off investors

- Unpredictable effects: Trips are subjective and can last up to 15 hours, complicating laboratory testing.

Pharma startups are responding by developing new classes of drugs:

- “Neuroplastogens”: All the warm and fuzzy feelings of connection without the hallucinations

- Ultra-short, intense trips: Newer compounds that cause very intense trips lasting only minutes, “at the time scale of a dental cleaning”.

For all the talk of a mental health revolution, psychedelics may deliver little more than business as usual, says Dr Hager.